GARNL3 inhibitors are chemical compounds designed to specifically inhibit the activity of the GTPase-activating Rap/Ran-GEF domain-like protein 3 (GARNL3). GARNL3 is a member of the Ras superfamily of small GTPases, which are involved in various cellular processes, including cell signaling, cytoskeletal dynamics, and vesicular trafficking. Structurally, GARNL3 inhibitors often contain motifs that facilitate binding to the active site of the GARNL3 protein, blocking its ability to interact with its physiological partners and downstream signaling pathways. These inhibitors typically function by interfering with the guanine nucleotide exchange factor (GEF) activity of GARNL3, preventing the activation of its associated GTPase targets. By modulating the nucleotide exchange process, these compounds effectively inhibit the normal cellular processes regulated by GARNL3, making them important tools for studying the biochemical and cellular functions of this protein.
The chemical design of GARNL3 inhibitors usually features high selectivity for the GARNL3 protein, ensuring minimal cross-reactivity with other GTPase-activating proteins. This selectivity is achieved through molecular structures that precisely match the binding pockets or active sites of GARNL3, allowing for specific inhibition. Various structural scaffolds can be used to develop these inhibitors, ranging from small molecules to larger macrocyclic compounds, each optimized to balance potency, stability, and bioavailability. Due to their ability to precisely target GARNL3, these inhibitors are often utilized in research to dissect the role of GARNL3 in cell biology. They allow researchers to explore how GARNL3 influences processes such as cytoskeletal reorganization, cell migration, and intracellular transport. As research tools, GARNL3 inhibitors are valuable in mapping the functional contributions of this protein within signaling pathways and in understanding the broader regulatory networks in which GARNL3 is involved.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K, which can alter the phosphorylation state and activity of proteins downstream. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Also targets PI3K, potentially affecting protein interactions and functions in related pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Binds mTOR, possibly affecting signaling pathways that regulate protein synthesis and degradation. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Specifically inhibits AKT, which can modulate multiple downstream proteins. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, thereby potentially altering transcription factor activity and protein expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Inhibits MEK, which could affect MAPK/ERK pathway proteins and their functions. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
P38 MAPK inhibitor, could change the phosphorylation state of dependent proteins. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK1, potentially affecting proteins downstream in the MAPK/ERK pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, can affect the degradation of a wide range of proteins. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor, may stabilize proteins that regulate the ubiquitin-proteasome pathway. | ||||||